RCMI Coordinating Center (RCMI CC) Header Logo

Giulio Francia

Faculty RankAssociate Professor
InstitutionUniversity of Texas at El Paso
DepartmentBiological Sciences
Address500 W. University Avenue - Room 5.144
Bioscience Research Building, Room 5.144
El Paso TX 79968
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    I began my career by starting my PhD at the Imperial Cancer Research Fund in London, UK, which has since evolved into Cancer UK. I chose to study the process by which tumors spread, or metastasis, that had fascinated me as an undergraduate, and I began my research career by seeking for new genes whose expression changes as tumors become more metastatic. After my PhD, I trained as a post-doc in Toronto, Canada, on aspects of metastasis, therapies for metastatic disease, and tumor resistance to therapy. I now plan to set up a research program that is internationally recognized for pioneering new ideas, and for generating models to help translate laboratory findings into the clinic - by developing new metastatic tumor models, and by refining those I have already established. I have developed the first model of spontaneously metastatic Her-2 positive breast cancer that can be monitored as mice bearing the disease are treated with clinically relevant anti-Her-2 strategies (Francia et al MCT 2008, and CCR 2009). The impact of this work has subsequently led to three editorials (Francia et al Cancer Cell 2009, Nat Rev Cancer 2011, and Francia and Kerbel Nat. Biotech 2010) where I put forward the hypothesis that testing laboratory models of metastatic disease is essential to identify mechanisms by which tumors respond to current therapies in the clinic, and by which they develop resistance to current treatments. I now want to test my hypothesis by developing two new models of human breast cancer that endogenously over-express Her-2.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Orlandi P, Banchi M, Vaglini F, Carli M, Aringhieri S, Bandini A, Pardini C, Viaggi C, Lai M, Al? G, Ottani A, Vandini E, Guidi P, Bernardeschi M, La Rocca V, Francia G, Fontanini G, Pistello M, Frenzilli G, Giuliani D, Scarselli M, Bocci G. Melanocortin receptor 4 as a new target in melanoma therapy: Anticancer activity of the inhibitor ML00253764 alone and in association with B-raf inhibitor vemurafenib. Biochem Pharmacol. 2024 01; 219:115952. PMID: 38036189.
      Citations:    Fields:    Translation:HumansAnimalsCells
    2. Qiu C, Wang X, Batson SA, Wang B, Casiano CA, Francia G, Zhang JY. A Luminex Approach to Develop an Anti-Tumor-Associated Antigen Autoantibody Panel for the Detection of Prostate Cancer in Racially/Ethnically Diverse Populations. Cancers (Basel). 2023 Aug 11; 15(16). PMID: 37627091.
    3. Liu X, Chipurupalli S, Jiang P, Tavasoli M, Yoo BH, McPhee M, Mazinani S, Francia G, Kerbel RS, Rosen KV. ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth. Cell Death Dis. 2022 Aug 06; 13(8):687. PMID: 35933456.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    4. Carcamo B, Francia G. Cyclic Metronomic Chemotherapy for Pediatric Tumors: Six Case Reports and a Review of the Literature. J Clin Med. 2022 May 18; 11(10). PMID: 35628975.
    5. Valenzuela P, Oaxaca D, Di Desidero T, Parra K, Rodriguez G, Manciu M, Allegrini G, Falcone A, Bocci G, Kirken RA, Francia G. Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients. Clin Exp Med. 2021 Feb; 21(1):149-159. PMID: 33048259.
      Citations: 3     Fields:    Translation:Humans
    6. Banchi M, Orlandi P, Gentile D, Al? G, Fini E, Fontanini G, Francia G, Bocci G. Synergistic activity of linifanib and irinotecan increases the survival of mice bearing orthotopically implanted human anaplastic thyroid cancer. Am J Cancer Res. 2020; 10(7):2120-2127. PMID: 32775005.
    7. Rolih V, Caldeira J, Bolli E, Salameh A, Conti L, Barutello G, Riccardo F, Magri J, Lamolinara A, Parra K, Valenzuela P, Francia G, Iezzi M, Pericle F, Cavallo F. Development of a VLP-Based Vaccine Displaying an xCT Extracellular Domain for the Treatment of Metastatic Breast Cancer. Cancers (Basel). 2020 Jun 08; 12(6). PMID: 32521631.
    8. Di Desidero T, Orlandi P, Gentile D, Banchi M, Al? G, Kusmic C, Armanetti P, Cayme GJ, Menichetti L, Fontanini G, Francia G, Bocci G. Pharmacological effects of vinorelbine in combination with lenvatinib in anaplastic thyroid cancer. Pharmacol Res. 2020 08; 158:104920. PMID: 32461187.
      Citations: 7     Fields:    Translation:HumansAnimals
    9. Xing M, Li P, Wang X, Li J, Shi J, Qin J, Zhang X, Ma Y, Francia G, Zhang JY. Overexpression of p62/IMP2 can Promote Cell Migration in Hepatocellular Carcinoma via Activation of the Wnt/?-Catenin Pathway. Cancers (Basel). 2019 Dec 18; 12(1). PMID: 31861402.
    10. Manciu M, Hosseini S, Di Desidero T, Allegrini G, Falcone A, Bocci G, Kirken RA, Francia G. Optimization of biomarkers-based classification scores as progression-free survival predictors: an intuitive graphical representation. Future Sci OA. 2018 12; 4(10):FSO346. PMID: 30450233.
    11. Xu L, Gordon R, Farmer R, Pattanayak A, Binkowski A, Huang X, Avram M, Krishna S, Voll E, Pavese J, Chavez J, Bruce J, Mazar A, Nibbs A, Anderson W, Li L, Jovanovic B, Pruell S, Valsecchi M, Francia G, Betori R, Scheidt K, Bergan R. Precision therapeutic targeting of human cancer cell motility. Nat Commun. 2018 06 22; 9(1):2454. PMID: 29934502.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    12. Fricke IB, De Souza R, Costa Ayub L, Francia G, Kerbel R, Jaffray DA, Zheng J. Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice. PLoS One. 2018; 13(5):e0196892. PMID: 29723251.
      Citations: 3     Fields:    Translation:HumansAnimalsCells
    13. Orlandi P, Di Desidero T, Salvia G, Muscatello B, Francia G, Bocci G. Metronomic vinorelbine is directly active on Non Small Cell Lung Cancer cells and sensitizes the EGFRL858R/T790M cells to reversible EGFR tyrosine kinase inhibitors. Biochem Pharmacol. 2018 06; 152:327-337. PMID: 29660315.
      Citations: 14     Fields:    Translation:HumansCells
    14. Chowdhury R, Gales D, Valenzuela P, Miller S, Yehualaeshet T, Manne U, Francia G, Samuel T. Bromoethylindole (BEI-9) redirects NF-?B signaling induced by camptothecin and TNFa to promote cell death in colon cancer cells. Apoptosis. 2017 Dec; 22(12):1553-1563. PMID: 29116428.
      Citations: 3     Fields:    Translation:HumansCells
    15. Di Desidero T, Antonelli A, Orlandi P, Ferrari SM, Fioravanti A, Al? G, Fontanini G, Basolo F, Francia G, Bocci G. Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer. Cancer Lett. 2017 12 28; 411:35-43. PMID: 28964784.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    16. Riesco-Martinez M, Parra K, Saluja R, Francia G, Emmenegger U. Resistance to metronomic chemotherapy and ways to overcome it. Cancer Lett. 2017 08 01; 400:311-318. PMID: 28259819.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    17. Parra K, Valenzuela P, Lerma N, Gallegos A, Reza LC, Rodriguez G, Emmenegger U, Di Desidero T, Bocci G, Felder MS, Manciu M, Kirken RA, Francia G. Impact of CTLA-4 blockade in conjunction with metronomic chemotherapy on preclinical breast cancer growth. Br J Cancer. 2017 01; 116(3):324-334. PMID: 28056464.
      Citations: 25     Fields:    Translation:AnimalsCells
    18. Di Desidero T, Derosa L, Galli L, Orlandi P, Fontana A, Fioravanti A, Marconcini R, Giorgi M, Campi B, Saba A, Lucchesi S, Felipetto R, Danesi R, Francia G, Allegrini G, Falcone A, Bocci G. Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients. Invest New Drugs. 2016 12; 34(6):760-770. PMID: 27557783.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    19. Manciu FS, Ciubuc JD, Parra K, Manciu M, Bennet KE, Valenzuela P, Sundin EM, Durrer WG, Reza L, Francia G. Label-Free Raman Imaging to Monitor Breast Tumor Signatures. Technol Cancer Res Treat. 2017 08; 16(4):461-469. PMID: 27381847.
      Citations: 8     Fields:    Translation:HumansCells
    20. Robles-Escajeda E, Das U, Ortega NM, Parra K, Francia G, Dimmock JR, Varela-Ramirez A, Aguilera RJ. A novel curcumin-like dienone induces apoptosis in triple-negative breast cancer cells. Cell Oncol (Dordr). 2016 Jun; 39(3):265-77. PMID: 26920032.
      Citations: 43     Fields:    Translation:HumansCells
    21. Li Y, Francia G, Zhang JY. p62/IMP2 stimulates cell migration and reduces cell adhesion in breast cancer. Oncotarget. 2015 Oct 20; 6(32):32656-68. PMID: 26416451.
      Citations: 24     Fields:    Translation:HumansCells
    22. Derosa L, Galli L, Orlandi P, Fioravanti A, Di Desidero T, Fontana A, Antonuzzo A, Biasco E, Farnesi A, Marconcini R, Francia G, Danesi R, Falcone A, Bocci G. Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients. Cancer. 2014 Dec 15; 120(24):3923-31. PMID: 25111199.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    23. Di Desidero T, Fioravanti A, Orlandi P, Canu B, Giannini R, Borrelli N, Man S, Xu P, Fontanini G, Basolo F, Kerbel RS, Francia G, Danesi R, Bocci G. Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. J Clin Endocrinol Metab. 2013 Sep; 98(9):E1465-73. PMID: 23969186.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    24. Kerbel RS, Guerin E, Francia G, Xu P, Lee CR, Ebos JM, Man S. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. Breast. 2013 Aug; 22 Suppl 2:S57-65. PMID: 24074794.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    25. Chow A, Wong A, Francia G, Man S, Kerbel RS, Emmenegger U. Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy. Invest New Drugs. 2014 Feb; 32(1):47-59. PMID: 23728939.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    26. Alkins R, Burgess A, Ganguly M, Francia G, Kerbel R, Wels WS, Hynynen K. Focused ultrasound delivers targeted immune cells to metastatic brain tumors. Cancer Res. 2013 Mar 15; 73(6):1892-9. PMID: 23302230.
      Citations: 98     Fields:    Translation:HumansAnimalsCells
    27. Bocci G, Fioravanti A, Orlandi P, Di Desidero T, Natale G, Fanelli G, Viacava P, Naccarato AG, Francia G, Danesi R. Metronomic ceramide analogs inhibit angiogenesis in pancreatic cancer through up-regulation of caveolin-1 and thrombospondin-1 and down-regulation of cyclin D1. Neoplasia. 2012 Sep; 14(9):833-45. PMID: 23019415.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    28. Cruz-Mu?oz W, Jaramillo ML, Man S, Xu P, Banville M, Collins C, Nantel A, Francia G, Morgan SS, Cranmer LD, O'Connor-McCourt MD, Kerbel RS. Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. Cancer Res. 2012 Oct 01; 72(19):4909-19. PMID: 22865454.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    29. Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS. Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models. Gut. 2013 Feb; 62(2):259-71. PMID: 22543158.
      Citations: 46     Fields:    Translation:HumansAnimalsCells
    30. Francia G, Shaked Y, Hashimoto K, Sun J, Yin M, Cesta C, Xu P, Man S, Hackl C, Stewart J, Uhlik M, Dantzig AH, Foster FS, Kerbel RS. Low-dose metronomic oral dosing of a prodrug of gemcitabine (LY2334737) causes antitumor effects in the absence of inhibition of systemic vasculogenesis. Mol Cancer Ther. 2012 Mar; 11(3):680-9. PMID: 22188817.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    31. Francia G, Cruz-Munoz W, Man S, Xu P, Kerbel RS. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat Rev Cancer. 2011 Feb; 11(2):135-41. PMID: 21258397.
      Citations: 163     Fields:    Translation:Animals
    32. Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia. 2011 Jan; 13(1):40-8. PMID: 21245939.
      Citations: 28     Fields:    Translation:HumansAnimalsCells
    33. Tang TC, Man S, Xu P, Francia G, Hashimoto K, Emmenegger U, Kerbel RS. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. Neoplasia. 2010 Nov; 12(11):928-40. PMID: 21076618.
      Citations: 32     Fields:    Translation:HumansAnimalsCells
    34. Francia G, Kerbel RS. Raising the bar for cancer therapy models. Nat Biotechnol. 2010 Jun; 28(6):561-2. PMID: 20531333.
      Citations: 22     Fields:    Translation:HumansAnimals
    35. Emmenegger U, Francia G, Shaked Y, Kerbel RS. Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. Recent Results Cancer Res. 2010; 180:165-83. PMID: 20033383.
      Citations: 14     Fields:    Translation:HumansCells
    36. Francia G, Man S, Lee CJ, Lee CR, Xu P, Mossoba ME, Emmenegger U, Medin JA, Kerbel RS. Comparative impact of trastuzumab and cyclophosphamide on HER-2-positive human breast cancer xenografts. Clin Cancer Res. 2009 Oct 15; 15(20):6358-66. PMID: 19825954.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    37. Mutsaers AJ, Francia G, Man S, Lee CR, Ebos JM, Wu Y, Witte L, Berry S, Moore M, Kerbel RS. Dose-dependent increases in circulating TGF-alpha and other EGFR ligands act as pharmacodynamic markers for optimal biological dosing of cetuximab and are tumor independent. Clin Cancer Res. 2009 Apr 01; 15(7):2397-405. PMID: 19276250.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    38. Francia G, Emmenegger U, Kerbel RS. Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. Cancer Cell. 2009 Jan 06; 15(1):3-5. PMID: 19111874.
      Citations: 18     Fields:    Translation:HumansCells
    39. Francia G, Emmenegger U, Lee CR, Shaked Y, Folkins C, Mossoba M, Medin JA, Man S, Zhu Z, Witte L, Kerbel RS. Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using beta-human choriogonadotropin secreting tumor cell lines. Mol Cancer Ther. 2008 Oct; 7(10):3452-9. PMID: 18852148.
      Citations: 14     Fields:    Translation:HumansAnimalsCells
    40. Ebos JM, Lee CR, Bogdanovic E, Alami J, Van Slyke P, Francia G, Xu P, Mutsaers AJ, Dumont DJ, Kerbel RS. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. Cancer Res. 2008 Jan 15; 68(2):521-9. PMID: 18199548.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    41. Emmenegger U, Shaked Y, Man S, Bocci G, Spasojevic I, Francia G, Kouri A, Coke R, Cruz-Munoz W, Ludeman SM, Colvin OM, Kerbel RS. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice. Mol Cancer Ther. 2007 Aug; 6(8):2280-9. PMID: 17671082.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    42. Munoz R, Man S, Shaked Y, Lee CR, Wong J, Francia G, Kerbel RS. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 2006 Apr 01; 66(7):3386-91. PMID: 16585158.
      Citations: 104     Fields:    Translation:HumansAnimalsCells
    43. Francia G, Dav? MV, Montresor E, Colato C, Ferdeghini M, Lo Cascio V. Long-term quiescence of ectopic Cushing's syndrome caused by pulmonary neuroendocrine tumor (typical carcinoid) and tumorlets: spontaneous remission or therapeutic effect of bromocriptine? J Endocrinol Invest. 2006 Apr; 29(4):358-62. PMID: 16699304.
      Citations: 4     Fields:    Translation:Humans
    44. du Manoir JM, Francia G, Man S, Mossoba M, Medin JA, Viloria-Petit A, Hicklin DJ, Emmenegger U, Kerbel RS. Strategies for delaying or treating in vivo acquired resistance to trastuzumab in human breast cancer xenografts. Clin Cancer Res. 2006 Feb 01; 12(3 Pt 1):904-16. PMID: 16467105.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    45. Emmenegger U, Morton GC, Francia G, Shaked Y, Franco M, Weinerman A, Man S, Kerbel RS. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res. 2006 Feb 01; 66(3):1664-74. PMID: 16452226.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    46. Francia G, Green SK, Bocci G, Man S, Emmenegger U, Ebos JM, Weinerman A, Shaked Y, Kerbel RS. Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents. Mol Cancer Ther. 2005 Oct; 4(10):1484-94. PMID: 16227397.
      Citations: 12     Fields:    Translation:HumansAnimalsCells
    47. Shaked Y, Emmenegger U, Francia G, Chen L, Lee CR, Man S, Paraghamian A, Ben-David Y, Kerbel RS. Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. Cancer Res. 2005 Aug 15; 65(16):7045-51. PMID: 16103050.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    48. Ma L, Francia G, Viloria-Petit A, Hicklin DJ, du Manoir J, Rak J, Kerbel RS. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 2005 Jun 15; 65(12):5365-73. PMID: 15958585.
      Citations: 18     Fields:    Translation:HumansCells
    49. Bocci G, Man S, Green SK, Francia G, Ebos JM, du Manoir JM, Weinerman A, Emmenegger U, Ma L, Thorpe P, Davidoff A, Huber J, Hicklin DJ, Kerbel RS. Increased plasma vascular endothelial growth factor (VEGF) as a surrogate marker for optimal therapeutic dosing of VEGF receptor-2 monoclonal antibodies. Cancer Res. 2004 Sep 15; 64(18):6616-25. PMID: 15374976.
      Citations: 62     Fields:    Translation:HumansAnimalsCells
    50. Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol. 2004 Aug; 24(15):6837-49. PMID: 15254249.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    51. Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004 Jun 01; 64(11):3994-4000. PMID: 15173013.
      Citations: 42     Fields:    Translation:Animals
    52. Green SK, Francia G, Isidoro C, Kerbel RS. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. Mol Cancer Ther. 2004 Feb; 3(2):149-59. PMID: 14985455.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    53. Bocci G, Francia G, Man S, Lawler J, Kerbel RS. Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy. Proc Natl Acad Sci U S A. 2003 Oct 28; 100(22):12917-22. PMID: 14561896.
      Citations: 137     Fields:    Translation:HumansAnimalsCells
    54. Kao RH, Francia G, Poulsom R, Hanby AM, Hart IR. Application of differential display, with in situ hybridization verification, to microscopic samples of breast cancer tissue. Int J Exp Pathol. 2003 Oct; 84(5):207-12. PMID: 14690479.
      Citations: 2     Fields:    Translation:HumansCells
    55. Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, Bohlen P, Hicklin DJ, Bergers G, Kerbel RS. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res. 2002 May 15; 62(10):2731-5. PMID: 12019144.
      Citations: 111     Fields:    Translation:HumansAnimalsCells
    56. Hokao R, Francia G. Differential display. Methods Mol Med. 2001; 57:297-305. PMID: 21340906.
      Citations: 1     Fields:    
    57. Francia G, Poulsom R, Hanby AM, Mitchell SD, Williams G, Mckee P, Hart IR. Identification by differential display of a protein phosphatase-2A regulatory subunit preferentially expressed in malignant melanoma cells. Int J Cancer. 1999 Aug 27; 82(5):709-13. PMID: 10417769.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    58. Kao RH, von Schlippe M, Francia G, Powell J, Hart IR. Identification of changes in gene expression associated with minimal residual disease. Cancer Metastasis Rev. 1999; 18(1):3-13. PMID: 10505542.
      Citations: 1     Fields:    Translation:HumansAnimals
    59. Francia G, Mitchell SD, Moss SE, Hanby AM, Marshall JF, Hart IR. Identification by differential display of annexin-VI, a gene differentially expressed during melanoma progression. Cancer Res. 1996 Sep 01; 56(17):3855-8. PMID: 8752144.
      Citations: 29     Fields:    Translation:HumansAnimalsCells
    60. Price NT, Francia G, Hall L, Proud CG. Guanine nucleotide exchange factor for eukaryotic initiation factor-2. Cloning of cDNA for the delta-subunit of rabbit translation initiation factor-2B. Biochim Biophys Acta. 1994 Mar 01; 1217(2):207-10. PMID: 8110836.
      Citations: 6     Fields:    Translation:AnimalsCells
    Francia's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (286)
    Co-Authors (7)
    Similar People (60)
    Same Department Expand Description
    RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

    For technical support please contact support